Boston Scientific (NYSE:BSX) stock climbed 5% Monday after the medical device maker announced a study has shown its Watchman FLX device was superior to oral anti-coagulant medication in reducing ...

Boston Scientific commenced enrollment of its SIMPLIFY trial, SIMPLIFY trial in the third quarter, which will study WATCHMAN FLX Pro with the simplified post-implant drug regimen. Macroeconomic ...

One of the standout products in Boston Scientific’s portfolio is the Watchman FLX Left Atrial Appendage Closure (LAAC) device. Recent clinical trial results from the OPTION study demonstrated ...

and Boston Scientific Corp ... traction in the United States and outside for its the next generation WATCHMAN FLX and FLX Pro, as well as contribution from accretive acquisitions are important ...

Boston Scientific Corporation BSX ... traction in the United States and outside for its next-generation WATCHMAN FLX and FLX Pro, as well as contribution from accretive acquisitions like Silk ...

Boston Scientific delivered another strong quarter, exceeding expectations in revenue and EPS. The company’s growth is underpinned by robust adoption of FARAPULSE and WATCHMAN, with significant ...

Boston Scientific Corporation develops ... and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices ...

One of the standout products in Boston Scientific's portfolio is the Watchman FLX Left Atrial Appendage Closure (LAAC) device. Recent clinical trial results from the OPTION study demonstrated superior ...

(PG), Boston Scientific Corp ... traction in the United States and outside for its the next generation WATCHMAN FLX and FLX Pro, as well as contribution from accretive acquisitions are important ...

Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Boston Scientific Corporation (BSX) and ConocoPhillips (COP), as well as a ...